|
|
Alum-TLR7 |
|
Vaxjo ID |
317 |
|
Vaccine Adjuvant Name |
Alum-TLR7 |
|
Description |
A new type of vaccine adjuvant based on a TLR7 agonist adsorbed to alum. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
vaccine adjuvant based on a TLR7 agonist adsorbed to alum (Alum-TLR7) |
|
Structure |
A TLR7 agonist adsorbed to alum (Aluminum Hydroxide). |
|
Function |
Alum-TLR7 also drives antibody response towards Th1 isotypes. This adjuvant was also able to increase immunogenicity of all polysaccharides of a multicomponent glycoconjugate vaccine CRM197-MenACWY. Furthermore, we found that Alum-TLR7 increases anti-polysaccharide immune response even in the presence of a prior immune response against the carrier protein. Finally, we demonstrate that Alum-TLR7 adjuvant effect requires a functional TLR7. Taken together, our data support the use of Alum-TLR7 as adjuvant for glycoconjugate vaccines. |
| References |
Buonsanti et al., 2016: Buonsanti C, Balocchi C, Harfouche C, Corrente F, Galli Stampino L, Mancini F, Tontini M, Malyala P, Bufali S, Baudner B, De Gregorio E, Valiante NM, O'Hagan DT, Rappuoli R, D'Oro U. Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines. Scientific reports. 2016; 6; 29063. [PubMed: 27439378].
|
|
